AU2017252507B2 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents

Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function Download PDF

Info

Publication number
AU2017252507B2
AU2017252507B2 AU2017252507A AU2017252507A AU2017252507B2 AU 2017252507 B2 AU2017252507 B2 AU 2017252507B2 AU 2017252507 A AU2017252507 A AU 2017252507A AU 2017252507 A AU2017252507 A AU 2017252507A AU 2017252507 B2 AU2017252507 B2 AU 2017252507B2
Authority
AU
Australia
Prior art keywords
leucine
acetyl
subject
mobility
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017252507A
Other languages
English (en)
Other versions
AU2017252507A1 (en
Inventor
Mallory Factor
Michael Strupp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of AU2017252507A1 publication Critical patent/AU2017252507A1/en
Application granted granted Critical
Publication of AU2017252507B2 publication Critical patent/AU2017252507B2/en
Priority to AU2022256077A priority Critical patent/AU2022256077A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2017252507A 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function Active AU2017252507B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022256077A AU2022256077A1 (en) 2016-04-19 2022-10-17 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
GB1606834.8 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022256077A Division AU2022256077A1 (en) 2016-04-19 2022-10-17 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (2)

Publication Number Publication Date
AU2017252507A1 AU2017252507A1 (en) 2018-11-08
AU2017252507B2 true AU2017252507B2 (en) 2022-07-21

Family

ID=58633040

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017252507A Active AU2017252507B2 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
AU2022256077A Abandoned AU2022256077A1 (en) 2016-04-19 2022-10-17 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022256077A Abandoned AU2022256077A1 (en) 2016-04-19 2022-10-17 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Country Status (27)

Country Link
US (4) US10905670B2 (enExample)
EP (2) EP4501406A3 (enExample)
JP (3) JP7387264B2 (enExample)
KR (4) KR102413754B1 (enExample)
CN (2) CN109069463B (enExample)
AU (2) AU2017252507B2 (enExample)
BR (1) BR112018071547A2 (enExample)
CA (1) CA3021155A1 (enExample)
DK (1) DK3445351T3 (enExample)
ES (1) ES2994242T3 (enExample)
FI (1) FI3445351T3 (enExample)
HR (1) HRP20241552T1 (enExample)
HU (1) HUE069219T2 (enExample)
IL (3) IL310508A (enExample)
LT (1) LT3445351T (enExample)
MD (1) MD3445351T2 (enExample)
MX (2) MX388461B (enExample)
NZ (1) NZ747307A (enExample)
PL (1) PL3445351T3 (enExample)
PT (1) PT3445351T (enExample)
RS (1) RS66142B1 (enExample)
RU (1) RU2745912C2 (enExample)
SG (2) SG11201809031XA (enExample)
SI (1) SI3445351T1 (enExample)
SM (1) SMT202400459T1 (enExample)
WO (1) WO2017182802A1 (enExample)
ZA (1) ZA201806849B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
CN109789114A (zh) 2016-08-11 2019-05-21 内在生物技术有限公司 神经退行性疾病的治疗剂
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US12145899B2 (en) 2018-12-06 2024-11-19 Intrabio Ltd. Deuterated analogs of acetyl-leucine
KR20210135272A (ko) * 2019-03-02 2021-11-12 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
US12171852B1 (en) 2023-07-18 2024-12-24 Sytheon Ltd Composition and methods for regulating melanogenesis
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
WO2008134844A1 (en) * 2007-05-08 2008-11-13 Multi Formulations Ltd. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
WO2019079536A1 (en) * 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KLAUS J. et al., "Dizziness and Unstable Gait in Old Age - Etiology, Diagnosis and Treatment", DEUTSCHES ARZTEBLATT INTERNATIONAL, (2015), vol. 112, no. 23, pages 387 - 393 *
MICHAEL S. et al., "Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, DE, (2013), vol. 260, no. 10, pages 2556 - 2561 *
SHINICHI I. et al., "Dizziness and Imbalance in the Elderly: Age-related Decline in the Vestibular System", AGING AND DISEASE, (2015), vol. 6, no. 1, pages 38 - 47 *
TATIANA B. et al., "Acetyl-DL-leucine in Niemann-Pick type C: A case series", NEUROLOGY, US, (2015), vol. 85, no. 16, pages 1368 - 1375 *
TIGHILET B. et al., "Comparative analysis of pharmacological treatments with N-acetyl-dl-leucine (Tanganil) and its two isomers on vestibular compensation: Behavioral investigation in the cat", EUR. J. PHARMA., (2015), p 342 - 349 *

Also Published As

Publication number Publication date
JP2019513814A (ja) 2019-05-30
AU2022256077A1 (en) 2022-11-17
CN109069463A (zh) 2018-12-21
KR102791288B1 (ko) 2025-04-03
KR102632670B1 (ko) 2024-02-01
LT3445351T (lt) 2024-11-25
JP2022024058A (ja) 2022-02-08
MX388461B (es) 2025-03-20
FI3445351T3 (fi) 2024-11-18
ZA201806849B (en) 2019-07-31
HUE069219T2 (hu) 2025-02-28
MD3445351T2 (ro) 2024-12-31
US20250332133A1 (en) 2025-10-30
IL293266A (en) 2022-07-01
RS66142B1 (sr) 2024-12-31
US20230346732A1 (en) 2023-11-02
EP4501406A2 (en) 2025-02-05
KR20220038814A (ko) 2022-03-29
CN109069463B (zh) 2024-07-23
PL3445351T3 (pl) 2025-01-07
IL310508A (en) 2024-03-01
IL293266B2 (en) 2024-07-01
US12329733B2 (en) 2025-06-17
SMT202400459T1 (it) 2025-01-14
DK3445351T3 (da) 2024-11-04
EP3445351A1 (en) 2019-02-27
RU2018140131A3 (enExample) 2020-05-14
SG11201809031XA (en) 2018-11-29
RU2018140131A (ru) 2020-05-14
IL262379B (en) 2022-07-01
RU2021107001A (ru) 2021-04-12
KR20240018683A (ko) 2024-02-13
KR102413754B1 (ko) 2022-06-27
KR20180134398A (ko) 2018-12-18
CA3021155A1 (en) 2017-10-26
NZ747307A (en) 2025-10-31
US20190083438A1 (en) 2019-03-21
CN118593463A (zh) 2024-09-06
HRP20241552T1 (hr) 2025-01-17
JP2024123087A (ja) 2024-09-10
AU2017252507A1 (en) 2018-11-08
MX2018012739A (es) 2019-06-17
PT3445351T (pt) 2024-11-14
IL262379A (en) 2018-11-29
RU2745912C2 (ru) 2021-04-02
SG10202106190RA (en) 2021-07-29
JP7506046B2 (ja) 2024-06-25
EP3445351B1 (en) 2024-10-16
KR20220093386A (ko) 2022-07-05
US10905670B2 (en) 2021-02-02
JP7387264B2 (ja) 2023-11-28
MX2021014844A (es) 2022-01-18
ES2994242T3 (en) 2025-02-05
EP4501406A3 (en) 2025-03-26
US20210106548A1 (en) 2021-04-15
SI3445351T1 (sl) 2025-04-30
US11998518B2 (en) 2024-06-04
IL293266B1 (en) 2024-03-01
WO2017182802A1 (en) 2017-10-26
BR112018071547A2 (pt) 2019-03-06

Similar Documents

Publication Publication Date Title
US12329733B2 (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
AU2023202121B2 (en) Therapeutic agents for neurodegenerative diseases
EP3697406A1 (en) Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
HK40114671A (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
RU2837641C2 (ru) Ацетиллейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции
HK1262576A1 (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
HK1262576B (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
NZ787419A (en) Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive
BR122024012307A2 (pt) Uso de acetil-leucina ou um sal farmaceuticamente aceitável desta

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)